Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Smith & Nephew Snats ( (SNN) ).
On 2 February 2026, Smith & Nephew filed a six‑monthly block listing return covering the period from 1 August 2025 to 31 January 2026, detailing the status of shares available under several employee share and incentive schemes. Across its Global Share Plan 2010, ShareSave Plans (2012 and 2022), and International ShareSave Plans (2012 and 2022), the company reported no new share allotments and unchanged balances of 3,756, 432,252, 612,504, 126,126 and 35,210 unallotted securities respectively, while under the Global Share Plan 2020 it allotted 14,695 securities, reducing the unallotted balance there to 388,563. The filing signals routine administration of its employee equity programmes, with only modest dilution from share issuance during the period and substantial headroom remaining for future grants under the various plans.
The most recent analyst rating on (SNN) stock is a Hold with a $34.91 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Neutral.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the main drivers of its stock score. However, bearish technical indicators and a high P/E ratio temper the overall outlook. The company’s strategic initiatives, such as the share buyback, reflect confidence in its financial health, but challenges in emerging markets and tariff impacts pose risks.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a UK-based medical technology company that designs, manufactures and markets orthopaedic reconstruction implants, sports medicine and ENT products, and advanced wound management solutions for healthcare providers worldwide. Listed in the US as a foreign private issuer, the group uses equity-based incentive plans and sharesave schemes to align employees and executives with long-term shareholder value.
Average Trading Volume: 704,503
Technical Sentiment Signal: Strong Buy
Current Market Cap: $14.44B
For a thorough assessment of SNN stock, go to TipRanks’ Stock Analysis page.